<DOC>
	<DOCNO>NCT00747110</DOCNO>
	<brief_summary>The purpose study prove therapeutic equivalence safety once-daily 9 mg budesonide versus 3 g mesalazine 8-week treatment patient active ulcerative colitis .</brief_summary>
	<brief_title>Budesonide Capsules Versus Mesalazine Granules Active Ulcerative Colitis ( UC )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Signed informed consent , 2 . Men woman age 18 75 year , 3 . Active ulcerative colitis , except proctitis limit 15 cm ab ano , confirm endoscopy histology , 4 . Established disease ( presence blood mucus stool ) new diagnosis ( bloody stool occur least 14 day prior baseline visit ) , 5 . Clinical Activity Index ( CAI ) &gt; = 6 Endoscopical Index ( EI ) &gt; = 4 , 6 . Women childbearing potential , heterosexually active , apply highly effective method birth control , define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive method , intrauterine device ( IUDs ) , sexual abstinence , vasectomise partner . The investigator responsible determine whether subject adequate birth control study participation . 1 . Crohn 's disease , indeterminate colitis , ischaemic colitis , radiation colitis , microscopic colitis ( i.e. , collagenous colitis lymphocytic colitis ) , 2 . Toxic megacolon , 3 . Baseline stool positive germ cause bowel disease , 4 . Diarrhoea result presence symptomatic organic disease ( ) gastrointestinal tract , 5 . Active peptic ulcer disease , 6 . Haemorrhagic diathesis , 7 . Asthma , diabetes mellitus , infection , osteoporosis , glaucoma , cataract , cardiovascular disease careful medical monitoring ensure , 8 . Severe comorbidity substantially reduce life expectancy , 9 . Active colorectal cancer history colorectal cancer , 10 . Active malignancy colorectal cancer treatment anticancer drug last 5 year . Patients history cancer colorectal cancer least five year uneventful follow sign recurrence may eligible , 11 . Immunosuppressants within 3 month and/or corticosteroid ( oral , intravenous [ IV ] topical rectal ) within 4 week prior baseline , 12 . Current relapse occur maintenance treatment &gt; 2.4 g mesalazine per day , 13 . Abnormal renal function ( Serum Cystatin C &gt; upper limit normal [ ULN ] ) , 14 . Abnormal hepatic function ( ALT , AST AP &gt; = 2 x ULN ) liver cirrhosis , 15 . Known intolerance/hypersensitivity/resistance study drug drug similar chemical structure pharmacological profile , constituent study drug , 16 . Doubt patient 's cooperation , e.g. , addiction alcohol drug , 17 . Existing intended pregnancy breastfeeding , 18 . Participation another clinical trial within last 30 day , simultaneous participation another clinical trial , previous participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>5-ASA</keyword>
	<keyword>mesalamine</keyword>
	<keyword>mesalazine</keyword>
	<keyword>budesonide</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>